Abstract
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:.
To assess the effectiveness and safety of SARS-CoV-2-neutralising mAbs, including mAb fragments, to prevent infection with SARS-CoV-2 causing COVID-19; and to maintain the currency of the evidence, using a living systematic review approach.
| Original language | English |
|---|---|
| Article number | CD014945 |
| Journal | Cochrane Database of Systematic Reviews |
| Volume | 2021 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 20 May 2021 |
Bibliographical note
Funding Information:SS: is funded by the Federal Ministry of Education and Research, Germany (NaFoUniMedCovid19, funding number: 01KX2021; part of the project "COVIM", which was paid to the institution). I have participated in a study on kinetics of the neutralising antibody response to SARS-CoV-2 (www.biorxiv.org/content/10.1101/2021.01.26.428207v1). In this review, I will not be involved in risk of bias assessment, data extraction or interpretation, but will serve as content expert.
Funding Information:
The CEOsys project is funded under a scheme issued by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF))
Funding Information:
The research was supported by NHS Blood and Transplant and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Funding Information:
This protocol was published in collaboration with the Cochrane Central Editorial Service. We particularly thank Nuala Livingstone (Network Editor, Cochrane Editorial and Methods Department) and Robin Featherstone (Information Specialist, Cochrane Editorial and Methods Department).?We thank Carolyn Dor?e (Information Specialist, Systematic Review Initiative, NHS Blood and Transplant Oxford) for peer reviewing the search strategy. We thank Robin Featherstone (Information Specialist, Cochrane Editorial and Methods Department) for peer reviewing the platform trials search strategy. We thank Andrea Takeda for copyediting the protocol. We would also like to thank our peer reviewers Andrew Michelson?(Assistant Professor, Division of Pulmonary and Critical Care, Department of Medicine/Director, Critical Care Informatics?Research?Faculty Affiliate, Institute for Informatics Washington University in St Louis School of Medicine)?and?Professor Stephen Kent?(University of Melbourne)?for their helpful suggestions. The research was part of a project supported by the German Federal Ministry of Education and Research (NaFoUniMedCovid19, funding number: 01KX2021;?part of the projects 'COVIM' and 'CEOsys').?The contents of this document reflect only the authors' views and the German Ministry is not responsible for any use that may be made of the information it contains. The research was supported by NHS Blood and Transplant and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Funding Information:
The research was part of a project supported by the German Federal Ministry of Education and Research (NaFoUniMedCovid19, funding number: 01KX2021; part of the projects 'COVIM' and 'CEOsys'). The contents of this document reflect only the authors' views and the German Ministry is not responsible for any use that may be made of the information it contains.
Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.